| The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure. | |
| | |
MedLine Citation:
|
PMID: 11479476 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Endothelin-1, a potent vasoconstrictor, is elevated in congestive heart failure and is postulated to play a major role in the pathogenesis of the disease. Endothelin receptor antagonism may be a specific therapeutic approach. This study was designed to determine the effective dosage range, hemodynamic effects, and tolerability of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with advanced heart failure. METHODS: This randomized, double-blind, placebo-controlled multicenter trial enrolled 38 patients with symptomatic stable heart failure (New York Heart Association class III, left ventricular ejection fraction <35%) undergoing right heart catheterization. Patients were equally randomized to a 4-hour intravenous infusion of placebo or tezosentan in ascending doses (5, 20, 50, and 100 mg over 1 hour each). Angiotensin-converting enzyme inhibitors and diuretics were withheld 24hours before the study. Hemodynamics were measured during and for 4 hours after the infusion. RESULTS: Compared with placebo, tezosentan treatment produced a significant increase in cardiac index (treatment difference 0.59 L/min/m(2), P =.0001) and decreases in pulmonary and systemic vascular resistances (P </=.01) without changes in heart rate. Consistently greater decreases in pulmonary capillary wedge pressure, mean right atrial pressure, and pulmonary and arterial pressures with tezosentan did not reach statistical significance. Hemodynamic changes were dose dependent with maximal effects at 20 and 50 mg per hour. Tezosentan was well tolerated. Despite increased endothelin-1 concentrations, hemodynamic rebound was not observed. CONCLUSION: Tezosentan rapidly and dose dependently improved hemodynamics. The favorable effects on cardiac index and pulmonary and systemic vascular resistances without changes in heart rate may be beneficial in the treatment of acute heart failure. |
| | |
Authors:
|
C Schalcher; G Cotter; L Reisin; O Bertel; I Kobrin; T T Guyene; W Kiowski |
Related Documents
:
|
22578736 - Adherence to acc/aha performance measures for myocardial infarction in six middle-easte... 8656236 - Maximizing therapy in the advanced heart failure patient. 20123246 - Progressive improvement in cardiac performance with continuous aortic flow augmentation... 2685146 - Recent advances in therapy of congestive heart failure. 6624676 - Noninvasive diagnosis of persistent fetal circulation versus congenital cardiovascular ... 11863326 - Management of intermittent claudication: the importance of secondary prevention. |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: American heart journal Volume: 142 ISSN: 0002-8703 ISO Abbreviation: Am. Heart J. Publication Date: 2001 Aug |
Date Detail:
|
Created Date: 2001-07-31 Completed Date: 2001-08-30 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0370465 Medline TA: Am Heart J Country: United States |
Other Details:
|
Languages: eng Pagination: 340-9 Citation Subset: AIM; IM |
Affiliation:
|
University Hospital and Stadspital Triemli, Zürich, and Actelion Ltd, Allschwil, Switzerland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Dose-Response Relationship, Drug Double-Blind Method Endothelin-1 / blood, drug effects Epinephrine / blood Female Heart Failure / drug therapy* Heart Function Tests / drug effects Hemodynamics / drug effects* Humans Infusions, Intravenous Male Middle Aged Norepinephrine / blood Prospective Studies Pyridines / administration & dosage, blood, pharmacology*, therapeutic use* Receptors, Endothelin / antagonists & inhibitors* Tetrazoles / administration & dosage, blood, pharmacology*, therapeutic use* Vasodilator Agents / administration & dosage, blood, pharmacology*, therapeutic use* |
| Chemical | |
Reg. No./Substance:
|
0/Endothelin-1; 0/Pyridines; 0/Receptors, Endothelin; 0/Tetrazoles; 0/Vasodilator Agents; 0/tezosentan; 51-41-2/Norepinephrine; 51-43-4/Epinephrine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A functional myeloperoxidase polymorphic variant is associated with coronary artery disease in Frenc...
Next Document: Predictors of costs of caring for elderly patients discharged with heart failure.